Table 1.
Baseline Patient Characteristics
| Characteristic | All Patients (N = 104), No. (%) | Micafungin Prophylaxis (n = 83), No. (%) | Micafungin Treatment (n = 21), No. (%) | P Value |
|---|---|---|---|---|
| Demographics | ||||
| Age, y, median (range) | 54.3 (21.6–70.1) | 54.2 (21.6–70.1) | 59.0 (26.7–69.0) | .51 |
| Sex, female | 54 (52) | 44 (53) | 10 (48) | .66 |
| Race | .74 | |||
| White | 76 (73) | 58 (70) | 18 (86) | |
| African American | 13 (13) | 11 (13) | 2 (10) | |
| Asian | 9 (9) | 8 (10) | 1 (5) | |
| Underlying disease | .15 | |||
| Acute leukemia | 57 (55) | 42 (51) | 15 (71) | |
| Chronic leukemia | 3 (3) | 1 (1) | 2 (10) | |
| Myelodysplastic syndrome | 19 (18) | 18 (22) | 1 (5) | |
| Multiple myeloma | 2 (2) | 2 (2) | 0 | |
| Lymphoma | 22 (21) | 19 (23) | 3 (14) | |
| Stem cell transplant characteristicsa | 84 (81) | 78 (94) | 6 (29) | |
| Stem cell source | .23 | |||
| Cord blood | 28 (33) | 24 (31) | 4 (67) | |
| Peripheral blood stem cells | 52 (62) | 50 (64) | 2 (33) | |
| Bone marrow | 4 (5) | 4 (5) | 0 | |
| Conditioning regimen, myeloablativeb | 73 (87) | 68 (87) | 5 (83) | .58 |
| Donor–recipient matching | .41 | |||
| Matched related | 23 (27) | 21 (27) | 2 (33) | |
| Matched unrelated | 21 (25) | 21 (27) | 0 | |
| Mismatched unrelated | 40 (48) | 36 (46) | 4 (67) | |
| Stem cell manipulation, T-cell depletion | 25 (30) | 24 (31) | 1 (17) | .31 |
| Acute graft-vs-host disease, grade 2 or higher | 44 (52) | 42 (54) | 2 (33) | .66 |
| Reason(s) for micafungin selectionc | ||||
| Abnormal liver function testsd | 69 (66) | 67 (81) | 2 (10) | <.0001 |
| Abnormal renal function | 5 (5) | 3 (4) | 2 (10) | .26 |
| Central nervous system adverse event | 4 (4) | 2 (2) | 2 (10) | .18 |
| Drug–drug interactions | 10 (10) | 9 (11) | 1 (5) | .68 |
| Othere | 23 (22) | 6 (7) | 17 (81) | <.0001 |
| Baseline abnormal liver functionf | ||||
| Aspartate aminotransferase | 14 (13) | 0 | 14 (17) | .07 |
| Alanine aminotransferase | 32 (31) | 30 (36) | 2 (10) | .02 |
| Alkaline phosphatase | 26 (25) | 24 (29) | 2 (10) | .09 |
| Total bilirubin | 12 (12) | 11 (13) | 1 (5) | .45 |
a Although all patients included in the study received an allogeneic stem cell transplant (SCT), intermittent high-dose micafungin was started posttransplant in 84 of 104 (80.8%). Hence, baseline SCT characteristics are described only for these patients.
b Thirteen and 22 patients received high and low total body irradiation, respectively. The remaining 38 patients were conditioned with busulfan/fludarabine/melphalan (n = 20), melphalan/fludarabine (n = 10), busulfan/fludarabine (n = 7), and other (n = 1).
c Patients might have had >1 reason to be started on micafungin.
d Abnormal baseline liver function as a reason to use micafungin was based on the treating clinicians' assessment and not on the definition of liver impairment used in this study.
e Micafungin was used in addition to another antifungal agent as combination therapy (n = 13), lack of insurance coverage for azoles (n = 4), baseline prolonged QT interval (n = 1), underlying hepatitis C infection (n = 1), and other (n = 4).
f Abnormal baseline liver function was defined as ≥1 of the following: aspartate and alanine aminotransferase >3 times the upper limit of normal (ULN) and alkaline phosphatase and total bilirubin >2 times the ULN.